The folate receptor as a molecular target for tumor-selective radionuclide delivery

Nuclear Medicine and Biology

Volumn 30, Issue 8, 2003, Pages 811-817

  Ke, Chun Yen ^a   Mathias, Carla J ^a   Green, Mark A ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Folate binding protein; Folate receptor; Radionuclide imaging; Radiopharmaceutical; Tumor targeting

Indexed keywords

COPPER 64; FOLATE BINDING PROTEIN; GALLIUM 67; INDIUM 111; PENTETATE INDIUM FOLATE IN 111; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; HUMAN; ISOTOPE LABELING; MOLECULAR DYNAMICS; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR AFFINITY; STEREOCHEMISTRY;

EID: 0347224284     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00117-3     Document Type: Conference Paper

References (95)

1. Anderson R.G.W., Kamen B.A., Rothberg K.G., Lacy S.W. Potocytosis Sequestration and transport of small molecules by caveolae . Science. 255:1992;410-411.
2. Rothberg K.G., Ying Y.S., Kolhouse J.F., Kamen B.A., Anderson R.G. The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. J Cell Biol. 110:1990;637-649.
3. Forgac M. Structure and function of vacuolar class of ATP-driven pumps. Physiological Rev. 69:1989;765-795.
4. Darnell J.E. Molecular Cell Biology. 1990;326-333 WH Freeman, San Francisco.
5. Pastan I., Willingham M.C. Endocytosis. 1985;1-40 Plenum Press, New York.
6. Leamon C.P., Low P.S. Cytotoxicity of momordin-folate conjugates in cultured human cells. J Biol Chem. 267:1992;24966-24971.
7. Leamon C.P., Low P.S. Delivery of macromolecules into living cells a method that exploits folate receptor endocytosis . Proc Natl Acad USA. 88:1991;5572-5576.
8. Antony A.C., Kane M.A., Portillo R.M., Elwood P.C., Kolhouse J.F. Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. J Biol Chem. 260:1985;14911-14917.
9. Henderson G.B., Tsuji J.M., Kumar H.P. Mediated uptake of folate by a high-affinity binding protein in sublines of L1210 cells adapted to nanomolar concentrations of folate. J Membrane Biol. 101:1988;247-258.
10. Pizzorno G., Cashmore A.R., Moroson B.A., Cross A.D., Smith A.K., Marling-Cason M., Kamen B.A., Beardsley G.P. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. J Biol Chem. 268:1993;1017-1023.
11. Sirotnak F.M. Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport biological significance and implications for improved therapy of human cancer . Cancer Res. 45:1985;3992-4000.
12. Westerhof G.R., Schornagel J.H., Kathmann I., Jackman A.L., Rosowsky A., Forsch R.A., Hynes J.B., Boyle F.T., Peters G.J., Pinedo H.M., Jansen G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes correlates of molecular-structure and biological activity . Molecular Pharmacology. 48:1995;459-471.
13. Antony A.C. The biological chemistry of folate receptors. Blood. 79:1992;2807-2820.
14. Jansen G. Receptor-, and carrier-mediated transport systems for folates, and antifolates. Jackman A.L. Antifolate drugs in cancer therapy. 1999;293-321 Humana Press, Totowa NJ.
15. Garin-Chesa P., Campbell I., Saigo P.E., Lewis J.L. Jr, Old L.J., Rettig W.J. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol. 142:1993;557-567.
16. Stein R., Goldenberg D.M., Mattes M.J. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Int J Cancer. 47:1991;163-169.
17. Li P.Y., Del Vecchio S., Fonti R., Carriero M.V., Potena M.I., Botti G., Miotti S., Lastoria S., Menard S., Colnaghi M.I., Salvatore M. Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. J Nucl Med. 37:1996;665-672.
18. 2 fragments in ovarian carcinoma patients. Cancer Res. 53:1993;5413-5418.
19. Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 74:1997;193-198.
20. Williams W.M., Huang K.C. Renal tubular transport of folic acid and methotrexate in the monkey. Am J Physiol. 242:1982;F484-490.
21. Selhub J. The folate-binding protein of rat kidney. J Biol Chem. 259:1984;6601-6606.
22. Selhub J., Emmanouel D., Stavropoulos T., Arnold R. Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. Am J Physiol. 252:1987;F750-756.
23. Selhub J., Nakamura S., Carone F.A. Renal folate adsorption and the kidney folate binding protein. II. Microinfusion studies. Am J Physiol. 252:1987;F757-760.
24. Kamen B.A., Caston J.D. Identification of a folate binder in hog kidney. J Biol Chem. 250:1975;2203-2205.
25. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski V.R., Jennings D.S., Kamen B.A. Cellular localization of the folate receptor potential role in drug toxicity and folate homeostasis . Cancer Res. 52:1992;6708-6711.
26. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawsky V.R., Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
27. Holm J., Hansen S.I., Hoier-Madsen M., Birn H., Helkjaer P.-E. High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites Radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity . Archives of Biochemistry and Biophysics. 366:1999;183-191.
28. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines physiologic and clinical implications . Cancer. 73:1994;2432-2443.
29. Wu M., Gunning W., Ratnam M. Expression of folate receptor type α in relation to cell type, malignancy, and differentiation in ovary, uterus and cervix. Cancer Epidemiology, Biomarkers and Prevention. 8:1999;775-782.
30. Mantovani L.T., Miotti S., Menard S., Canevari S., Raspagliesi F., Bottini C., Bottero F., Colnaghi M.I. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer. 30A:1994;363-369.
31. + cells. Blood. 93:1999;3940-3948.
32. Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T. Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis and Rheumatism. 42:1999;1609-1616.
33. Spinella M.J., Brigle K.E., Sierra E.E., Goldman I.D. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem. 270:1995;7842-7849.
34. Holm J., Hansen S.I., Hoier-Madsen M., Helkjaer P.-E., Bzorek M. A high-affinity soluable folate receptor in fluids of non-neoplastic ovarian cysts Radioligand binding, molecular size, hydrophobic residue, and immunological properties . APMIS. 103:1995;862-868.
35. Baggnoli M., Canevari S., Figini M., Mezzanzanica D., Raspagliesi F., Tomassetti A., Miotti S. A step further in understanding the biology of the folate receptor in ovarian carcinoma. Gynecologic Oncology. 88:2003;S140-144.
36. Maziarz K.M., Monaco H.L., Shen F., Ratnam M. Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors α and β J Biol Chem. 274:1999;11086-11091.
37. Shen F., Wu M., Ross J.F., Miller D., Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification protein characterization and cell type specificity . Biochemistry. 34:1995;5660-5665.
38. Matherly L.H., Wong S.C., Angeles S.M., Taub J.W., Smith G.K. Distribution of the reduced folate carrier (RFC) versus the high affinity membrane folate binding protein (mFBP) in human tumors and tissues. Proc Am Assoc Cancer Res. 35:1994;307.
39. Shen F., Zheng X., Wang J., Ratnam M. Identification of amino acid residues that determine the differential ligand specificities of folate receptors α and β Biochemistry. 36:1997;6157-6163.
40. Wang H., Ross J.F., Ratnam M. Structure and regulation of a polymorphic gene encoding folate receptor type γ/γ'. Nucleic Acids Research. 26:1998;2132-2142.
41. Holm J., Hansen S.I., Hoier-Madsen M., Bostad L. High-affinity folate binding in human choroid plexus. Biochem J. 280:1991;267-271.
42. Weitman S.D., Frazier K.M., Kamen B.A. The folate receptor in central nervous system malignancies of childhood. J Neurol Oncol. 21:1994;107.
43. Treloar T., Grieve P.A., Nixon P.F. One-step affinity purification of folate-binding protein, amino whey protein. The Australian Journal of Dairy Technology. 55:2000;96.
44. Holm J., Hansen S.I. Ligand binding characteristics and aggregation behavior of purified cow's milk folate binding protein depends on the presence of amphiphatic substances including cholesterol, phospholipids and synthetic detergents. Bioscience Reports. 22:2002;431-441.
45. Holm J., Hansen S.I., Hoier-Madsen M. A combination of cation exchange and ligand-affinity chromatography for purification of two molecular species of the folate binding protein in human milk, one equipped with a hydrophobic glycosyl phosphatidylinositol tail characterization of hydrophobicity and electrical charge . Bioscience Reports. 22:2002;443-454.
46. Holm J., Hansen S.I. Ligand binding characteristics of two molecular forms, one equipped with a hydrophobic glycosyl phosphatidylinositol tail, of the folate binding protein purified from human milk. Bioscience Reports. 22:2002;455-463.
47. Brigle K.E., Spinella M.J., Westin E.H., Goldman I.D. Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochemical Pharmacology. 47:1994;337-345.
48. Wang X., Shen F., Freisheim J.H., Gentry L.E., Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochemical Pharmacology. 44:1992;1898-1901.
49. Smart E.J., Foster D.C., Ying Y.S., Kamen B.A., Anderson R.G.W. Protein kinase C activators inhibit receptor-mediated potocytosis by preventing internalization of caveolae. J Cell Biol. 124:1994;307-313.
50. Ward C.M., Acheson N., Seymour L.W. Folic acid targeting of protein conjugates into ascites tumour cells from ovarian cancer patients. J Drug Target. 8:2000;119-123.
51. Leamon C.P., Low P.S. Membrane folate binding proteins are responsible for the folate-protein conjugate endocytosis into cultured cells. Biochem J. 291:1993;855-860.
52. Turek J.J., Leamon C.P., Low P.S. Endocytosis of folate-protein conjugates Ultrastructural localization in KB cells . J Cell Sci. 106:1993;423-430.
53. Leamon C.P., Pastan I., Low P.S. Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J Biol Chem. 268:1993;24847-24854.
54. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Bio Chem. 269:1993;3198-3204.
55. Lee R.J., Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1233:1995;134-144.
56. Leamon C.P., Low P.S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target. 2:1994;101-112.
57. Li S., Deshmukh H.M., Huang L. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res. 15:1998;1540-1545.
58. Lu J.Y., Lowe D.A., Kennedy M.D., Low P.S. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J Drug Target. 7:1999;43-53.
59. Konda S.D., Aref M., Brechbiel M., Wiener E.C. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor work in progress . Invest Radiol. 35:2000;50-57.
60. Konda S.D., Aref M., Wang S., Brechbiel M., Wiener E.C. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA. 12:2001;104-113.
61. 99mTc-HYNIC-folate a novel receptor-based targeted radiopharmaceutical for tumor imaging . J Nucl Med. 40:1999;1563-1569.
62. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconj Chem. 7:1996;56-62.
63. Mathias C.J., Wang S., Lee R.J., Waters D.J., Low P.S., Green M.A. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med. 37:1996;1003-1008.
64. 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. Nucl Med Biol. 26:1999;23-25.
65. 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl. Med. Biol.: in press.
66. 111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconj Chem. 8:1997;673-679.
67. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med. 39:1998;1579-1585.
68. 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer initial clinical results . J Nucl Med. 44:2003;700-707.
69. Wedeking PW, Wager RE, Arunachalam T, Ramalingam K, Linder KE, Ranganathan RS, Nunn AD, Raju N, Tweedle M. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications U.S. Patent 6,093,382, July 2000:25.
70. Wedeking PW, Wager RE, Arunachalam T, Ramalingam K, Linder KE, Ranganathan RS, Nunn AD, Raju N, Tweedle M. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications. U.S. Patent 6,221,334, April 2001:4.
71. 99mTc]-Tc-DTPA-Folate and its evaluation as a folate-receptor- targeted radiopharmaceutical. Bioconj Chem. 11:2000;253-257.
72. 3-DTPA-Folate as a folate-receptor-targeted radiopharmaceutical. Nucl Med Biol. 29:2002;569-573.
73. Ke C.Y., Mathias C.J., Yang Z.F., Luo J., Low P.S., Waters D.J., Green M.A. Synthesis and evaluation of folate-bis(thiosemicarbazone) and folate-CYCLAM conjugates for possible use as folate-receptor-targeted copper radiopharmaceuticals. J Labelled Compd Radiopharm. 42:1999;S821-823.
74. 99mTc-based radiopharmaceutical . Bioconj Chem. 13:2002;1200-1210.
75. 111In-labeled folate conjugate of "octadentate-DTPA" J Nucl Med. 41:2000;232P.
76. 111In-DTPA conjugate of pteroic acid. J Nucl Med. 42:2001;114P-115P.
77. Mattes M.J., Major P.P., Goldenberg D.M., Dion A.S., Hutter R.V., Klein K.M. Patterns of antigen distribution in human carcinomas. Cancer Res. 50:(Suppl):1990;880S.
78. Boerman O.C., van Niekerk C.C., Makkink K., Hanselaar T.G., Kenemans P., Poels L.G. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int J Gynecol Pathol. 10:1991;15-25.
79. Miotti S., Facheris P., Tomassetti A., Bottero F., Bottini C., Ottone F., Colnaghi M.I., Bunni M.A., Priest D.G., Canevari S. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Biochem. 65:1997;479-491.
80. Miotti S., Canevari S., Menard S., Mezzanzanica D., Porro G., Pupa S.M., Regazzoni M., Tagliabue E., Colnaghi M.I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 39:1987;297-303.
81. Mezzanzanica D., Garrido M.A., Neblock D.S., Daddona P.E., Andrew S.M., Zurawski V.R., Segal D.M., Wunderlich J.R. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res. 51:1991;5716-5721.
82. Rothenberg S.P., daCosta M. Further observations on the folate-binding factor in some leukemic cells. J Clin Inves. 50:1971;719-726.
83. Westerhof G.R., Jansen G., van Emmerik N., Kathmann I., Rijksen G., Jackman A.L., Schornagel J.H. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells role of carrier- and receptor-mediated transport systems . Cancer Res. 51:1991;5507-5513.
84. Coney L.R., Tomasetti A., Carayannopoulos I., Frasca V., Kamen B.A., Colnaghi M.I., Zurawski V.R. Cloning of a tumor-associated antigen MOv18 and MOv19 antibodies recognize a folate-binding protein . Cancer Res. 51:1991;6125-6132.
85. Kamen B.A., Capdevila A. Receptor-mediated folate accumulation is regulated by cellular folate content. Proc Natl Acad Sci USA. 83:1986;5983-5987.
86. Campbell I.G., Jones T.A., Foulkes W.D., Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 51:1991;5329-5338.
87. Kalofonos H.P., Karamouzis M.V., Epenetos A.A. Radioimmunoscintigraphy in patients with ovarian cancer. Acta Oncologica. 40:2001;549-557.
88. van Zanten-Przybysz I., Molthoff C.F., Roos J.C., Verheijen R.H., van Hof A., Buist M.R., Prinssen H.M., den Hollander W., Kenemans P. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int J Cancer. 92:2001;106-114.
89. 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med. 41:2000;1168-1176.
90. Crippa F., Buraggi G.L., Dire E., Gasparini M., Seregni E., Canevari S., Gadina M., Presti M., Marini A., Seccamani E. Radioimmunoscintigraphy of ovarian cancer with the Mov18 monoclonal antibody. Eur J Cancer. 27:1991;724-729.
91. DuBeshter B., Lin J., Angel C., Poulter C.A. Gynecologic tumors. Rubin P. Clinical Oncology. 7th Ed. 1993;363-418 W. B. Saunders, Philadelphia.
92. Trimble E.L. The NIH Consensus Conference on ovarian cancer screening, treatment, and follow-up . Gynecol Oncol. 55:1994;S1-3.
93. Toffoli G., Russo A., Gallo A., Cernigoi C., Miotti S., Sorio R., Tumolo S., Boiocchi M. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer (Pred Oncol). 79:1998;121-126.
94. Kutsky R.J. Handbook of Vitamins, Minerals, and Hormones. 2nd ed :1981;273 Van Nostrand Reinhold, New York.
95. 111In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. Nucl Med Biol. 25:1998;585-587.